Novel therapeutic targets for enteric nervous system disorders

Area of Science:

• Gastroenterology
• Neurogastroenterology
• Pharmacology

Background:

• Significant unmet medical needs exist for treating functional gastrointestinal disorders such as irritable bowel syndrome (IBS), functional dyspepsia, and gastroesophageal reflux disease.
• These conditions often involve a neural component affecting the gastrointestinal system's intrinsic or extrinsic innervation.
• The market for effective IBS therapeutics is substantial, estimated at over $10 billion annually.

Purpose of the Study:

• To review the current understanding of neural targets in gastrointestinal disorders.
• To highlight promising therapeutic targets for developing new treatments.
• To discuss the potential of novel compounds for future therapies.

Main Methods:

• Literature review of recent advancements in neurogastroenterology.
• Analysis of identified neural targets and their associated receptors.
• Evaluation of the therapeutic potential of targeting specific transmitters and ion channels.

Main Results:

• Improved understanding of enteric neuron transmitters, receptors, and ion channels facilitates targeted therapy development.
• 5-hydroxytryptamine receptors are identified as highly promising targets.
• Other potential targets include opioid, cholecystokinin, tachykinin, cannabinoid, corticotropin-releasing factor, and protease-activated receptors, as well as ion channels.

Conclusions:

• Despite challenges in translating knowledge into effective therapies, identified neural targets offer significant promise.
• Development of new compounds with precise receptor specificity and pharmacodynamic profiles is crucial.
• Future research holds the potential to realize effective treatments for debilitating gastrointestinal disorders.